GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starton Therapeutics Inc (NAS:STA) » Definitions » Other Current Receivables

Starton Therapeutics (Starton Therapeutics) Other Current Receivables : $0.00 Mil (As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Starton Therapeutics Other Current Receivables?

Starton Therapeutics's Other Current Receivables for the quarter that ended in Jun. 2023 was $0.00 Mil.


Starton Therapeutics Other Current Receivables Historical Data

The historical data trend for Starton Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starton Therapeutics Other Current Receivables Chart

Starton Therapeutics Annual Data
Trend Mar21 Mar22 Mar23
Other Current Receivables
- - -

Starton Therapeutics Quarterly Data
Mar21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23
Other Current Receivables Get a 7-Day Free Trial - - - - -

Starton Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Starton Therapeutics Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Starton Therapeutics's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Starton Therapeutics (Starton Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
215 College Road, Suite No.300, Paramus, NJ, USA, 07652
Starton Therapeutics Inc is a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, and longer. Starton's proprietary continuous delivery technology can increase the efficacy of approved drugs, make them more tolerable, and expand their potential use.

Starton Therapeutics (Starton Therapeutics) Headlines

No Headlines